The Emotional Impact of Surveillance for Pancreatic Cancer
Surveillance Program in High-risk Individuals for Pancreatic Cancer: Prospective Analysis of the Emotional Impact
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
- Diagnostic test: Barratt Simplified Measure of Social Status (BSMSS)
- Diagnostic test: Global Assessment of Functioning scale (GAF)
- Diagnostic test: General Self-Efficacy Scale (GSES)
- Diagnostic test: Perceived Stress Scale (PSS)
- Diagnostic test: Coping Orientation to Problems Experienced (Brief COPE),
- Diagnostic test: Multidimensional Scale of Perceived Social Support (MSPSS)
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
VR
-
Verona, VR, Italy, 37134
- University Hospital of Verona
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Being enrolled in the Institutional surveillance program for pancreatic cancer
- Ability to understand the details and implications of a study protocol.
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Psychometric assessment group
Arms to whom the psychometric assessment will be administered
|
Questionnaire that evaluates cultural identity, educational level and occupation of the subject and the subject's parents and spouse (if any)
Used to measure overall levels of functionality of an individual
Psychometric scale that is designed to assess optimistic self-beliefs to cope with a variety of difficult demands in life
To assess the perceived stress
It evaluates the subject's coping style through investigation of problem-solving abilities and emotional fluctuation, as a response to stressful situations
to explore the subject's social support system
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Barratt Simplified Measure of Social Status
Time Frame: Baseline
|
Evaluation of cultural identity, educational level and occupation of the subject and the subject's parents and spouse (if any)
|
Baseline
|
|
Barratt Simplified Measure of Social Status
Time Frame: 2-years
|
Evaluation of cultural identity, educational level and occupation of the subject and the subject's parents and spouse (if any)
|
2-years
|
|
Global Assessment of Functioning scale
Time Frame: Baseline
|
measure overall levels of functionality of an individual
|
Baseline
|
|
Global Assessment of Functioning scale
Time Frame: 2-years
|
measure overall levels of functionality of an individual
|
2-years
|
|
General Self-Efficacy Scale
Time Frame: Baseline
|
Self-report scale correlated to emotion, optimism, work
|
Baseline
|
|
General Self-Efficacy Scale
Time Frame: 2-years
|
Self-report scale correlated to emotion, optimism, work
|
2-years
|
|
Perceived Stress Scale
Time Frame: Baseline
|
Assessment of the perceived stress
|
Baseline
|
|
Perceived Stress Scale
Time Frame: 2-year
|
Assessment of the perceived stress
|
2-year
|
|
Coping Orientation to Problems Experienced
Time Frame: Baseline
|
evaluation of the subject's coping style through investigation of problem-solving abilities and emotional fluctuation, as a response to stressful situations
|
Baseline
|
|
Coping Orientation to Problems Experienced
Time Frame: 2-years
|
evaluation of the subject's coping style through investigation of problem-solving abilities and emotional fluctuation, as a response to stressful situations
|
2-years
|
|
Multidimensional Scale of Perceived Social Support
Time Frame: Baseline
|
to explore the subject's social support system
|
Baseline
|
|
Multidimensional Scale of Perceived Social Support
Time Frame: 2-years
|
to explore the subject's social support system
|
2-years
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Paiella S, Capurso G, Cavestro GM, Butturini G, Pezzilli R, Salvia R, Signoretti M, Crippa S, Carrara S, Frigerio I, Bassi C, Falconi M, Iannicelli E, Giardino A, Mannucci A, Laghi A, Laghi L, Frulloni L, Zerbi A. Results of First-Round of Surveillance in Individuals at High-Risk of Pancreatic Cancer from the AISP (Italian Association for the Study of the Pancreas) Registry. Am J Gastroenterol. 2019 Apr;114(4):665-670. doi: 10.1038/s41395-018-0414-z.
- Maheu C, Vodermaier A, Rothenmund H, Gallinger S, Ardiles P, Semotiuk K, Holter S, Thayalan S, Esplen MJ. Pancreatic cancer risk counselling and screening: impact on perceived risk and psychological functioning. Fam Cancer. 2010 Dec;9(4):617-24. doi: 10.1007/s10689-010-9354-5.
- Konings IC, Harinck F, Kuenen MA, Sidharta GN, Kieffer JM, Aalfs CM, Poley JW, Smets EM, Wagner A, van Rens A, Vleggaar FP, Ausems MG, Fockens P, van Hooft JE, Bruno MJ, Bleiker EM; Dutch research group on pancreatic cancer surveillance in high-risk individuals. Factors associated with cancer worries in individuals participating in annual pancreatic cancer surveillance. Fam Cancer. 2017 Jan;16(1):143-151. doi: 10.1007/s10689-016-9930-4.
- Harinck F, Nagtegaal T, Kluijt I, Aalfs C, Smets E, Poley JW, Wagner A, van Hooft J, Fockens P, Bruno M, Bleiker EM. Feasibility of a pancreatic cancer surveillance program from a psychological point of view. Genet Med. 2011 Dec;13(12):1015-24. doi: 10.1097/GIM.0b013e31822934f5.
- Konings IC, Sidharta GN, Harinck F, Aalfs CM, Poley JW, Kieffer JM, Kuenen MA, Smets EM, Wagner A, van Hooft JE, van Rens A, Fockens P, Bruno MJ, Bleiker EM. Repeated participation in pancreatic cancer surveillance by high-risk individuals imposes low psychological burden. Psychooncology. 2016 Aug;25(8):971-8. doi: 10.1002/pon.4047. Epub 2015 Dec 3.
- Cazacu IM, Luzuriaga Chavez AA, Saftoiu A, Bhutani MS. Psychological impact of pancreatic cancer screening by EUS or magnetic resonance imaging in high-risk individuals: A systematic review. Endosc Ultrasound. 2019 Jan-Feb;8(1):17-24. doi: 10.4103/eus.eus_25_18.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Psy-FPC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Cancer
-
NCT06388967RecruitingPancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Pancreatic Carcinoma | Pancreatic Cancer Non-resectable | Pancreatic Cancer Stage III | Pancreatic Cancer Stage | Pancreatic Cancer Stage II
-
NCT02414100WithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
-
NCT07277452Not yet recruiting
-
NCT07436741Not yet recruiting
-
NCT01959672CompletedPancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
-
NCT03825289TerminatedMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer
-
NCT02349867CompletedPancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
-
NCT05642962Active, not recruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma Metastatic
-
NCT02345460TerminatedPancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Poorly Differentiated Malignant Neoplasm | Undifferentiated Pancreatic Carcinoma
-
NCT03977233RecruitingPancreatic Neoplasms | Pancreas Adenocarcinoma | Pancreatic Cancer Resectable | Cancer of Pancreas | Pancreatic Cancer Non-resectable | Pancreatic Ductal Adenocarcinoma (PDAC) | Pancreatic Cancer, Adult
Clinical Trials on Barratt Simplified Measure of Social Status (BSMSS)
-
NCT02885792UnknownCardiovascular Disease | Schizophrenia
-
NCT02960789Completed
-
NCT05096338Active, not recruitingCardiovascular Diseases | Prostate Cancer | Drug-Related Side Effects and Adverse Reactions | Cardiotoxicity
-
NCT05078190Active, not recruitingCardiovascular Diseases | Breast Cancer | Drug-Related Side Effects and Adverse Reactions | Cardiotoxicity
-
NCT06471595CompletedHypertension | Type 2 Diabetes Mellitus | Dyslipidemia | Pre-diabetes | Cardiometabolic Syndrome | Weight Loss Trial
-
NCT05871008Active, not recruitingKidney Cancer | Leukemia | Myeloid Leukemia | Breast Cancer | Multiple Myeloma | Hodgkin Lymphoma | Prostate Cancer | Bladder Cancer | Lymphoid Leukemia | Monocytic Leukemia
-
NCT07469566Not yet recruitingAutism Spectrum Disorder (ASD) | 7q11.23 Microduplication Syndrome (7DUP) | Neurodevelopmental Disorders (NDD)
-
NCT06451341Active, not recruiting
-
NCT04046575Active, not recruitingEsophageal Cancer | Cancer of the Esophagus | Esophagus Cancer